» Articles » PMID: 28718444

Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure

Overview
Journal Trends Cancer
Publisher Cell Press
Specialty Oncology
Date 2017 Jul 19
PMID 28718444
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Although most ovarian cancer patients are highly responsive to chemotherapy, they frequently present with recurrent metastatic lesions that result in poor overall survival, a situation that has not changed in the last 20 years. This review discusses new insights into the regulation of ovarian cancer chemoresistance with a focus on the emerging role of immune and other host cells. Here, we summarize the complex molecular pathways that regulate the interaction between tumor and host cells, discuss the limitations of current in vitro and in vivo models for translational studies, and present perspectives for the development of innovative therapies.

Citing Articles

Single-cell encoded gene silencing for high-throughput combinatorial siRNA screening.

Guo F, Ji X, Xiong C, Sun H, Liang Z, Yan-Do R Nat Commun. 2024; 15(1):9985.

PMID: 39562763 PMC: 11576956. DOI: 10.1038/s41467-024-53419-7.


Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review.

Tan L, Ni Y, Huang Z, Yan J, Wu M, Zhang Z Future Oncol. 2024; 20(26):1943-1960.

PMID: 39129672 PMC: 11498025. DOI: 10.1080/14796694.2024.2373680.


Deregulated circRNAs in Epithelial Ovarian Cancer With Activity in Preclinical Models: Identification of Targets and New Modalities for Therapeutic Intervention.

Weidle U, Birzele F Cancer Genomics Proteomics. 2024; 21(3):213-237.

PMID: 38670587 PMC: 11059596. DOI: 10.21873/cgp.20442.


Reciprocal crosstalk between Th17 and mesothelial cells promotes metastasis-associated adhesion of ovarian cancer cells.

Neuhaus F, Lieber S, Shinkevich V, Steitz A, Raifer H, Roth K Clin Transl Med. 2024; 14(4):e1604.

PMID: 38566518 PMC: 10988119. DOI: 10.1002/ctm2.1604.


EM-transcriptomic signature predicts drug response in advanced stages of high-grade serous ovarian carcinoma based on ascites-derived primary cultures.

Constantinescu D, Sorop A, Ghionescu A, Lixandru D, Herlea V, Bacalbasa N Front Pharmacol. 2024; 15:1363142.

PMID: 38510654 PMC: 10953505. DOI: 10.3389/fphar.2024.1363142.